; (6) the process by which States, localities, Territories, Tribes, and industry partners voluntarily choose to participate in the SCCT Program; and (7) any inefficiencies, deficiencies, or challenges related to the application or operation of the SCCT Program. (c) Report to Congress Not later than the deadline described in subsection (a) for the completion of the review under this section, the Comptroller General shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report on the results of such review. 110. Review of HHS efforts to ensure rapid production and domestic manufacturing capacity of medical countermeasures (a) In general Not later than 1 year after the date of the enactment of this Act, the Comptroller General of the United States shall conduct and complete a review examining the efforts of the Secretary of Health and Human Services to ensure that the United States is prepared to rapidly produce qualified countermeasures (as defined in section 319F–1 of the Public Health Service Act ( 42 U.S.C. 247d–6a )) in the event of a public health emergency declared under section 319 of the Public Health Service Act ( 42 U.S.C. 274d ). (b) Contents The review conducted under subsection (a) shall include a review of— (1) the efforts described in such subsection, including the Secretary’s efforts to transition from the Centers for Innovation and Advanced Drug Manufacturing program to any new efforts, including the National Biopharmaceutical Manufacturing Partnership and Industrial Base Expansion Connect; (2) the progress made toward the implementation of such efforts